Funding and Grants - eXoZymes has received a total of $17,697,378 in grants since inception, with $4,058,367 awarded in 2025 and $1,048,302 in 2024[35] - The company has received a $50,000 grant from the Gates Foundation for terpene synthesis, highlighting its engagement with non-government funding sources[34] - The company received a grant of approximately $1,000,000 from the Department of Defense in October 2024 to support biomanufacturing efforts[198] Business Model and Strategy - The company is focusing on low-volume, high-value compounds for nutraceuticals, which can also serve as active pharmaceutical ingredients (APIs)[36] - eXoZymes aims to leverage AI-designed exozymes to create scalable and sustainable biosolutions, differentiating from traditional synthetic biology approaches[26] - The commercialization strategy includes a focus on nutraceuticals to accelerate time to market and generate early revenue streams[46] - eXoZymes plans to evaluate transitioning select compounds into formal pharmaceutical development programs after the initial focus period[41] - The company is focused on developing joint ventures and licensing agreements to optimize or replace existing products in mature markets, generating both short-term and long-term revenue[61] - The business model emphasizes partnerships to share costs, risks, and revenues, particularly in the nutraceuticals-with-pharmaceutical-potential sector[54] - eXoZymes plans to commercialize NCT through a capital-light model leveraging contract manufacturers, aiming for consistent quality and improved manufacturing efficiency[72] Technology and Innovation - eXoZymes' biomanufacturing platform offers a cell-free approach that enhances control, efficiency, and cost-effectiveness in producing small molecule natural products[49] - The technology enables higher titers, yields, productivities, and purity compared to traditional synthetic biology methods, addressing scalability challenges[50] - The proprietary platform achieves over 99% food/pharma-grade purity and 6× faster production cycles than conventional methods, with over 99% reaction yield at pilot scale[69] - eXoZymes is developing multi-step cell-free biocatalysis systems, distinguishing itself from competitors that primarily use simpler one to two-step pathways[93] - The company is focused on biomanufacturing processes tailored to nutraceutical and pharmaceutical production, particularly for rare cannabinoids[77] Market and Competition - eXoZymes believes that partnerships will be essential for realizing the full potential of exozyme biosolutions in various markets[42] - The company faces competition from various firms in the synthetic biology space, including those focusing on enzyme engineering and biofuels[95] - The company competes with established firms and emerging startups in the synthetic biology market, facing challenges from companies with greater resources and experience[129] Financial Performance - For the year ended December 31, 2025, total operating costs increased by 63.8% to $9,716,471 compared to $5,932,105 in 2024[188] - Research and development costs rose by 98.4% to $3,706,991 in 2025, primarily due to higher salaries, bonuses, and laboratory expenses[189] - Cash and cash equivalents decreased by 68.7% to $3,039,343 as of December 31, 2025, down from $9,719,310 in 2024[190] - The company reported a net loss of $9,158,734 for 2025, a 56.3% increase from the net loss of $5,861,335 in 2024[188] - Working capital decreased by $7,114,450 to $2,372,687 as of December 31, 2025, compared to $9,487,137 in 2024[195] - Total assets decreased by 54.2% to $5,971,517 in 2025 from $13,034,404 in 2024[190] - The company incurred cash used in operating activities of $6,502,040 in 2025, an improvement from $8,505,650 in 2024[201] Intellectual Property and Licensing - eXoZymes has a robust intellectual property portfolio, including patents related to enzyme engineering and biomanufacturing processes, providing a competitive advantage[73] - The initial license fee for the agreement with The Regents of the University of California was $6,000, with a continuing maintenance fee of $2,500 per year[75] - The minimum annual royalty starts at $15,000 and increases to $50,000 in the third year, with a 2% royalty on net sales of therapeutics products and 1% on all other products[75] - The aggregate payments made to the Regents from 2019 to December 31, 2025, total $400,211, including patent fees and maintenance fees[78] - The company holds exclusive licenses from The Regents of the University of California for cell-free synthetic biochemistry technology, which imposes various developmental milestone obligations[138] Risks and Challenges - The company believes there is substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls[200] - The company faces potential challenges in obtaining regulatory approvals for its novel bio-synthesized compounds, which may delay development and commercialization[113] - The company lacks manufacturing and distribution capabilities and plans to seek partners for commercialization, which is critical for generating product revenue[124] - Future collaborations are essential for research and commercialization, but risks include potential non-performance by collaborators and competition from their independent developments[126] - The company is currently concentrated on a small number of biosolution projects, which poses risks if these products cannot be commercialized[122] Corporate Governance and Compliance - The company incurs significant legal and compliance costs as a public company, which may impact its financial performance[147] - The company may not be able to maintain effective internal controls over financial reporting, which could lead to a loss of confidence in its financial statements[153] - The company has not reported any cybersecurity breaches during the fiscal year ended December 31, 2025, but acknowledges potential risks associated with cyber attacks[171] - The company has retained outside consultants to enhance its information technology and cybersecurity measures, focusing on continuous improvement[174] Employee and Workforce - As of December 31, 2025, eXoZymes has approximately 32 full-time employees, including 9 with doctoral degrees, and plans to expand its workforce across multiple departments[101] Market Conditions - The synthetic biology market is rapidly evolving, and eXoZymes must continuously adapt to market demands to remain competitive[112] - Potential recessionary indicators may impact the general business environment and capital markets, affecting the company's operations[213] - The company does not believe inflation has materially affected its operations, although it continues to monitor supply chain issues and tariffs[212]
Invizyne Technologies Inc(IZTC) - 2025 Q4 - Annual Report